Teva Pharmaceutical Industries LTD.
Volume 164 · 164 F.T.C. 1062
Cite this decision
Teva Pharmaceutical Industries LTD., 164 F.T.C. 1062 (2017). Consumer Law Library, https://consumerlawlibrary.org/decisions/v164-0021
Report an error in this record (decision id v164-0021)
Cited by 0 later FTC decisions
Cites
Text (OCR of the scan at left; may contain errors)
IN THE MATTER OF TEVA PHARMACEUTICAL INDUSTRIES LTD.
AND ALLERGAN PLC Docket No. C-4589. Order, July 18, 2017 Letter notifying Teva Pharmaceutical Industries Ltd. of the Commission’s decision to waive prior approval and public comment regarding modifications to the supply agreement.
LETTER WAIVING PRIOR APPROVAL AND COMMENT FOR MODIFICATIONS TO A SUPPLY AGREEMENT Ian R. Conner, Esq.
Kirkland & Ellis LLP Re: In the Matter of Teva Pharmaceutical Industries Ltd, et al. Docket No. C.4589 Dear Mr. Conner:
This.is in reference to a request for approval filed by Teva Pharmaceutical Industries Ltd. (“Teva”) and received on June 27, 2017 (“Request”). Pursuant to the Decision and Order in Docket No. C-4589, Teva requests Commission approval of its proposal to make certain modifications to the supply agreement between Dr. Reddy’s, a Commission-approved acquirer in this matter, and Teva.
After consideration of Teva’s Request and pursuant to the authority delegated to me under Rule 2.41(f)(5)(ii) of the Commission’s Rules of Practice, 16 C.F.R. § 2.4l(f)(5)(ii), I hereby waive the requirements for Commission approval and the public comment period for the modifications to the supply agreement described in Teva’s Request If you have further questions, please contact David von Nirschl, the Compliance staff attorney assigned to this matter. Mr..von Nirschl can be reached at 202-326-3213 or [email protected].
IMPAX LABORATORIES, INC. 1063 Interlocutory Orders, Etc.